News & Events
- Microbiome and Bile Acid Restoration was Consistent Across Three Clinical Trials of Rbx2660 for Recurrent Clostridioides Difficile Infection: A Combined Analysis
- Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
- Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
- Genetic Analysis AS: Mandatory notification of trade – Primary Insider
- Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market
- Interim report January – March 2022
- Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
- Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
- Minutes from the Annual General Meeting 2022 in Genetic Analysis AS
- Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
- Notice of Annual General Meeting 2022
- Publication of Genetic Analysis’ 2021 Annual Report
- Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
- Microba Life Sciences and Ginkgo Bioworks announce partnership to discover novel live biotherapeutics
- Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting